Advertisement

Hematologic Disease in Implantation Failure

  • Shelby A. Neal
  • Jason M. Franasiak
  • Richard T. Scott
Chapter

Abstract

Successful embryo implantation involves a number of events that occur at the microvascular level. Hematologic pathology, specifically inherited and acquired thrombophilias, has been proposed as a potential etiology for implantation failure. This idea has largely evolved from the robust body of literature surrounding thrombophilias and recurrent pregnancy loss. The impact of thrombophilias on recurrent implantation failure is less clear, although it is thought to have a similar underlying mechanism, namely, that microthrombosis causes disturbed blood flow to the endometrium and, in the case of recurrent implantation failure, impairs the initial vascularization process that is necessary for successful implantation to occur. In this chapter, the available literature regarding the potential role of thrombophilias in implantation failure and the evidence for possible therapeutic options will be reviewed.

Keywords

Inherited thrombophilia Acquired thrombophilia Recurrent implantation failure 

References

  1. 1.
    Parazzini F, Acaia B, Faden D, Lovotti M, Marelli G, Cortelazzo S. Antiphospholipid antibodies and recurrent abortion. Obstet Gynecol. 1991;77(6):854–8.PubMedGoogle Scholar
  2. 2.
    Balasch J, Creus M, Fábregues F, Reverter JC, Carmona F, Tàssies D, et al. Antiphospholipid antibodies and human reproductive failure. Hum Reprod. 1996;11(10):2310–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Rai RS, Regan L, Clifford K, Pickering W, Dave M, Mackie I, et al. Antiphospholipid antibodies and beta 2-glycoprotein-I in 500 women with recurrent miscarriage: results of a comprehensive screening approach. Hum Reprod. 1995;10(8):2001–5.CrossRefPubMedGoogle Scholar
  4. 4.
    MacLean MA, Cumming GP, McCall F, Walker ID, Walker JJ. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol. 1994;101(2):103–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Branch DW, Gibson M, Silver RM. Clinical practice. Recurrent miscarriage. N Engl J Med. 2010;363(18):1740–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Di Simone N, D’Ippolito S, Marana R, Di Nicuolo F, Castellani R, Pierangeli SS, et al. Antiphospholipid antibodies affect human endometrial angiogenesis: protective effect of a synthetic peptide (TIFI) mimicking the phospholipid binding site of β2glycoprotein I. Am J Reprod Immunol. 2013;70(4):299–308.CrossRefPubMedGoogle Scholar
  7. 7.
    Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BJ, Hughes GR. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996;14(2):131–6.PubMedGoogle Scholar
  8. 8.
    Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992;80(4):614–20.PubMedGoogle Scholar
  9. 9.
    Yamada H, Atsumi T, Kobashi G, Ota C, Kato EH, Tsuruga N, et al. Antiphospholipid antibodies increase the risk of pregnancy-induced hypertension and adverse pregnancy outcomes. J Reprod Immunol. 2009;79(2):188–95.CrossRefPubMedGoogle Scholar
  10. 10.
    Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E, Mercier E, Ripart-Neveu S, Balducchi J-P, et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control “NOHA first” study. J Thromb Haemost. 2005;3(10):2178–84.CrossRefPubMedGoogle Scholar
  11. 11.
    Dudding TE, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost. 2004;91(4):700–11.PubMedGoogle Scholar
  12. 12.
    Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet Lond Engl. 2003;361(9361):901–8.CrossRefGoogle Scholar
  13. 13.
    Silver RM, Zhao Y, Spong CY, Sibai B, Wendel G, Wenstrom K, et al. Prothrombin gene G20210A mutation and obstetric complications. Obstet Gynecol. 2010;115(1):14–20.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Dizon-Townson D, Miller C, Sibai B, Spong CY, Thom E, Wendel G, et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol. 2005;106(3):517–24.CrossRefPubMedGoogle Scholar
  15. 15.
    Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol. 2002;101(1):6–14.CrossRefPubMedGoogle Scholar
  16. 16.
    Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340(1):9–13.CrossRefPubMedGoogle Scholar
  17. 17.
    Nurk E, Tell GS, Refsum H, Ueland PM, Vollset SE. Factor V Leiden, pregnancy complications and adverse outcomes: the Hordaland homocysteine study. QJM Mon J Assoc Physicians. 2006;99(5):289–98.CrossRefGoogle Scholar
  18. 18.
    D’Elia AV, Driul L, Giacomello R, Colaone R, Fabbro D, Di Leonardo C, et al. Frequency of factor V, prothrombin and methylenetetrahydrofolate reductase gene variants in preeclampsia. Gynecol Obstet Investig. 2002;53(2):84–7.CrossRefGoogle Scholar
  19. 19.
    Simon A, Laufer N. Assessment and treatment of repeated implantation failure (RIF). J Assist Reprod Genet. 2012;29(11):1227–39.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Nelen WL, Blom HJ, Steegers EA, den Heijer M, Eskes TK. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil Steril. 2000;74(6):1196–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Paidas MJ, D-HW K, Langhoff-Roos J, Arkel YS. Inherited thrombophilias and adverse pregnancy outcome: screening and management. Semin Perinatol. 2005;29(3):150–63.CrossRefPubMedGoogle Scholar
  22. 22.
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295–306.CrossRefPubMedGoogle Scholar
  23. 23.
    Vlachoyiannopoulos PG, Routsias JG. A novel mechanism of thrombosis in antiphospholipid antibody syndrome. J Autoimmun. 2010;35:248–55.CrossRefPubMedGoogle Scholar
  24. 24.
    Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol. 1996;87(4):489–93.CrossRefPubMedGoogle Scholar
  25. 25.
    Norwitz ER, Schust DJ, Fisher SJ. Implantation and the survival of early pregnancy. N Engl J Med. 2001;345(19):1400–8.CrossRefPubMedGoogle Scholar
  26. 26.
    Grandone E, Colaizzo D, Lo Bue A, Checola MG, Cittadini E, Margaglione M. Inherited thrombophilia and in vitro fertilization implantation failure. Fertil Steril. 2001;76(1):201–2.CrossRefPubMedGoogle Scholar
  27. 27.
    Azem F, Many A, Ben Ami I, Yovel I, Amit A, Lessing JB, et al. Increased rates of thrombophilia in women with repeated IVF failures. Hum Reprod. 2004;19(2):368–70.CrossRefPubMedGoogle Scholar
  28. 28.
    Qublan HS, Eid SS, Ababneh HA, Amarin ZO, Smadi AZ, Al-Khafaji FF, et al. Acquired and inherited thrombophilia: implication in recurrent IVF and embryo transfer failure. Hum Reprod. 2006;21(10):2694–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Di Nisio M, Rutjes AWS, Ferrante N, Tiboni GM, Cuccurullo F, Porreca E. Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis. Blood. 2011;118(10):2670–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Martinelli I, Taioli E, Ragni G, Levi-Setti P, Passamonti SM, Battaglioli T, et al. Embryo implantation after assisted reproductive procedures and maternal thrombophilia. Haematologica. 2003;88(7):789–93.PubMedGoogle Scholar
  31. 31.
    Rudick B, Su HI, Sammel MD, Kovalevsky G, Shaunik A, Barnhart K. Is factor V Leiden mutation a cause of in vitro fertilization failure? Fertil Steril. 2009;92(4):1256–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Simur A, Ozdemir S, Acar H, Colakoğlu MC, Görkemli H, Balci O, et al. Repeated in vitro fertilization failure and its relation with thrombophilia. Gynecol Obstet Investig. 2009;67(2):109–12.CrossRefGoogle Scholar
  33. 33.
    Vaquero E, Lazzarin N, Caserta D, Valensise H, Baldi M, Moscarini M, et al. Diagnostic evaluation of women experiencing repeated in vitro fertilization failure. Eur J Obstet Gynecol Reprod Biol. 2006;125(1):79–84.CrossRefPubMedGoogle Scholar
  34. 34.
    Coulam CB, Kaider BD, Kaider AS, Janowicz P, Roussev RG. Antiphospholipid antibodies associated with implantation failure after IVF/ET. J Assist Reprod Genet. 1997;14(10):603–8.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Kaider BD, Price DE, Roussev RG, Coulam CB. Antiphospholipid antibody prevalence in patients with IVF failure. Am J Reprod Immunol. 1996;35(4):388–93.CrossRefPubMedGoogle Scholar
  36. 36.
    Geva E, Yaron Y, Lessing JB, Yovel I, Vardinon N, Burke M, et al. Circulating autoimmune antibodies may be responsible for implantation failure in in vitro fertilization. Fertil Steril. 1994;62(4):802–6.CrossRefPubMedGoogle Scholar
  37. 37.
    el-Roeiy A, Gleicher N, Friberg J, Confino E, Dudkiewicz A. Correlation between peripheral blood and follicular fluid autoantibodies and impact on in vitro fertilization. Obstet Gynecol. 1987;70(2):163–70.PubMedGoogle Scholar
  38. 38.
    Martinuzzo M, Iglesias Varela ML, Adamczuk Y, Broze GJ, Forastiero R. Antiphospholipid antibodies and antibodies to tissue factor pathway inhibitor in women with implantation failures or early and late pregnancy losses. J Thromb Haemost. 2005;3(11):2587–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Buckingham KL, Stone PR, Smith JF, Chamley LW. Antiphospholipid antibodies in serum and follicular fluid—is there a correlation with IVF implantation failure? Hum Reprod. 2006;21(3):728–34.CrossRefPubMedGoogle Scholar
  40. 40.
    Birdsall MA, Lockwood GM, Ledger WL, Johnson PM, Chamley LW. Antiphospholipid antibodies in women having in-vitro fertilization. Hum Reprod. 1996;11(6):1185–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Denis AL, Guido M, Adler RD, Bergh PA, Brenner C, Scott RT. Antiphospholipid antibodies and pregnancy rates and outcome in in vitro fertilization patients. Fertil Steril. 1997;67(6):1084–90.CrossRefPubMedGoogle Scholar
  42. 42.
    Chilcott IT, Margara R, Cohen H, Rai R, Skull J, Pickering W, et al. Pregnancy outcome is not affected by antiphospholipid antibody status in women referred for in vitro fertilization. Fertil Steril. 2000;73(3):526–30.CrossRefPubMedGoogle Scholar
  43. 43.
    Practice Committee of the American Society for Reproductive Medicine. Anti-phospholipid antibodies do not affect IVF success. Fertil Steril. 2006;86(5 Suppl 1):S224–5.Google Scholar
  44. 44.
    Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174(5):1584–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol. 2010;115(6):1256–62.CrossRefPubMedGoogle Scholar
  46. 46.
    Backos M, Rai R, Baxter N, Chilcott IT, Cohen H, Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol. 1999;106(2):102–7.CrossRefPubMedGoogle Scholar
  47. 47.
    Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005;2:CD002859.Google Scholar
  48. 48.
    Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314(7076):253–7.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Harris EN, Gharavi AE, Hughes GR. Anti-phospholipid antibodies. Clin Rheum Dis. 1985;11(3):591–609.PubMedGoogle Scholar
  50. 50.
    Ermel LD, Marshburn PB, Kutteh WH. Interaction of heparin with antiphospholipid antibodies (APA) from the sera of women with recurrent pregnancy loss (RPL). Am J Reprod Immunol. 1995;33(1):14–20.CrossRefPubMedGoogle Scholar
  51. 51.
    Qublan H, Amarin Z, Dabbas M, Farraj A-E, Beni-Merei Z, Al-Akash H, et al. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial. Hum Fertil (Camb). 2008;11(4):246–53.CrossRefGoogle Scholar
  52. 52.
    Stern C, Chamley L, Norris H, Hale L, Baker HWG. A randomized, double-blind, placebo-controlled trial of heparin and aspirin for women with in vitro fertilization implantation failure and antiphospholipid or antinuclear antibodies. Fertil Steril. 2003;80(2):376–83.CrossRefPubMedGoogle Scholar
  53. 53.
    Urman B, Ata B, Yakin K, Alatas C, Aksoy S, Mercan R, et al. Luteal phase empirical low molecular weight heparin administration in patients with failed ICSI embryo transfer cycles: a randomized open-labeled pilot trial. Hum Reprod. 2009;24(7):1640–7.CrossRefPubMedGoogle Scholar
  54. 54.
    Berker B, Taşkin S, Kahraman K, Taşkin EA, Atabekoğlu C, Sönmezer M. The role of low-molecular-weight heparin in recurrent implantation failure: a prospective, quasi-randomized, controlled study. Fertil Steril. 2011;95(8):2499–502.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Shelby A. Neal
    • 1
    • 2
  • Jason M. Franasiak
    • 1
    • 2
  • Richard T. Scott
    • 1
    • 2
  1. 1.Sidney Kimmel Medical CollegeThomas Jefferson University PhiladelphiaPhiladelphiaUSA
  2. 2.IVI-RMA of New JerseyBasking RidgeUSA

Personalised recommendations